哌拉西林/他唑巴坦联合依替米星治疗支气管扩张患者感染疗效的分析  

Clinical effect of piperacillin-tazobactam combined with etimicin on treatment of bronchiectasia patients with infections

作　　者：陈刚[1] 徐永芳[1] 徐长青[1] 黄旭晴[1] 王斌[2] 

机构地区：[1]杭州师范大学附属医院呼吸科,浙江杭州310005 [2]杭州师范大学附属医院ICU,浙江杭州310005

出　　处：《中华医院感染学杂志》2016年第9期1970-1972,共3页Chinese Journal of Nosocomiology

基　　金：浙江省卫生厅医药卫生计划项目基金资助项目(2012KYA142)

摘　　要：目的探讨哌拉西林/他唑巴坦联合依替米星治疗支气管扩张患者感染的临床疗效。方法选择2012年4月-2015年8月医院住院治疗的80例支气管扩张发生感染患者,将其随机分为试验组和对照组,各40例,试验组给予哌拉西林/他唑巴坦联合依替米星治疗,对照组只给予哌拉西林/他唑巴坦治疗,对两组患者的临床症状指标及疗效进行对比分析;使用SPSS17.0软件对数据进行统计分析。结果试验组患者的临床症状改善时间明显短于对照组(P<0.05);血沉(ESR)、C-反应蛋白(CRP)、白细胞(WBC)计数在接受治疗后试验组均优于对照组(P<0.05);试验组总有效率为92.5%,明显优于对照组的70.0%(P<0.05);试验组患者治疗后呼气峰流速(PEF)、一秒用力呼气容积(FEV1)、用力肺活量比值(FEV1/FVC)明显优于对照组,两组比较差异均有统计学意义(P<0.05)。结论哌拉西林/他唑巴坦联合依替米星治疗支气管扩张发生感染具有良好的临床疗效,且不良反应低,值得在临床推广应用。OBJECTIVE To explore the clinical effect of piperacillin-tazobactam combined with etimicin on treatment of bronchiectasia patients with infections.METHODS A total of 80 bronchiectasia patients with infections who were hospitalized from Apr 2012 to Aug 2015 were enrolled in the study and randomly divided into the experimental group and the control group,with 40 cases in each.The experimental group was treated with piperacillin-tazobactam combined with etimicin,while the control group was only given piperacillin-tazobactam.The indicators of clinical symptoms and therapeutic effects were observed and compared between the two groups of patients,and the statistical analysis of data was performed with the use of SPSS17.0software.RESULTS The time of improvement of clinical symptoms was significantly shorter in the experimental group than in the control group（P〈0.05）.The erythrocyte sedimentation rate（ESR）,C-reactive protein（CRP）,and white blood cell（WBC）counts of the experimental group were better than those of the control group after the treatment（P〈0.05）.The total effective rate of the experimental group was 92.5%,significantly higher than 70.0% of the control group（P〈0.05）.The peak expiratory flow（PEF）,forced expiratory volume in one second（FEV1）,and FEV1/forced vital capacity（FVC）ratio were significantly better in the experimental group than in the control group（P〈0.05）.CONCLUSIONPiperacillin-tazobactam combined with etimicin can achieve significant clinical effect on treatment of the bronchiectasia patients with infections,with the incidence of adverse reactions low,and it is worthy to be promoted in the hospital.

关 键 词：哌拉西林/他唑巴坦 依替米星 支气管扩张 感染 

分 类 号：R978.1[医药卫生—药品]